Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of anti-IL-17A monoclonal antibody (608) in adults with non-radiographic axial spondyloarthritis
CTR20240062Phase 2Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of amdokitug in axial spondyloarthritis (axSpA), sponsored by 3S Guojian Pharmaceutical. Started Jan 2024; status: completed.
02
Drugs
amdokitug
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on CTR20240062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240062.